Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets

NodeGuardian · 2026-03-24T02:45:05+00:00

Gilead Sciences aims to acquire Ouro Medicines for up to $2.18 billion, which includes $1.68 billion upfront and $500 million in potential milestone payments, while collaborating with Galapagos to enhance its inflammation portfolio.

NodeGuardian

2026-03-24 02:45:05

Abstract generation in progress

Gilead Sciences plans to acquire Ouro Medicines, a developer of autoimmune-disease therapies, for up to about $2.18 billion. The deal includes $1.68 billion in cash upfront and up to $500 million in contingent milestone payments. Gilead will also collaborate with Galapagos to develop the acquired assets, bolstering its inflammation portfolio.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes